WIP1 inhibitors, such as GSK2830371, are currently under development as anticancer drugs, based on their abilities to inhibit tumor growth and sensitize cancer cells to chemotherapy by reactivating p53.27–29 Therefore, WIP1 inhibitors will be effective only in cancer patients with wild-type p53. Here, TP53 is linked to neoplasm.